

7 April 2022

To:  
SINGAPORE EXCHANGE SECURITIES  
TRADING LIMITED  
11 North Buona Vista Drive,  
#06-07 The Metropolis Tower 2,  
Singapore – 138589

**GLENMARK PHARMACEUTICALS LIMITED**

*(Incorporated with limited liability under the Indian Companies Act, 1956 with Registration No. 11-19982)*

**ANNOUNCEMENT**

**REPURCHASE OF US\$200,000,000 2.00 PER CENT. RESETTABLE ONWARD STARTING  
EQUITY-LINKED SECURITIES DUE 2022**

On 7 April 2022, Glenmark Pharmaceuticals Limited (the "**Company**") repurchased an aggregate principal amount of US\$75,000,000 of the US\$200,000,000 2.00 per cent. (ISIN: XS1426780125; Common Code: 142678012) (the "**Bonds**") (collectively, the "**Repurchase**"). The Repurchase was carried out by way of on-market purchases via The Hongkong and Shanghai Banking Corporation Limited. The Bonds are listed on the Singapore Exchange Securities Trading Limited.

The settlement and cancellation for the repurchased Bonds had completed on 7 April 2022. Following cancellation, the aggregate outstanding principal amount of the Bonds will be US\$750,000.

The Bonds were repurchased at a price of 125.26% of the principal amount plus accrued and unpaid interest.

**FOR GLENMARK PHARMACEUTICALS LIMITED**

7 April 2022

*This announcement is not an offer to purchase, a solicitation of an offer to purchase, an offer to sell, or a solicitation of an offer to sell, the Bonds. This announcement does not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law. This announcement is not for release, publication or distribution in or into, or to any person resident and/or located in, any jurisdiction where such release, publication or distribution is unlawful.*

*This announcement does not constitute an offer to sell or the solicitation of an offer to purchase any securities in the United States, India or any other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No securities may be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Any public offering of securities to be made in the United States will be made by means of a prospectus which will contain detailed information about the Company and its management, as well as its financial statements. No public offering of securities is to be made by the Company in the United States.*

**Glenmark Pharmaceuticals Ltd.**

Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India

T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: [www.glenmarkpharma.com](http://www.glenmarkpharma.com)

Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: [complianceofficer@glenmarkpharma.com](mailto:complianceofficer@glenmarkpharma.com)